Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$21.99
0.0%
$27.82
$20.19
$59.61
$1.05B1.41708,368 shs340,838 shs
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$80.37
$82.48
$39.40
$89.76
$3.58B1.55626,604 shsN/A
Glaukos Co. stock logo
GKOS
Glaukos
$109.17
+1.4%
$94.66
$54.38
$110.73
$5.50B1.08637,878 shs106,865 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$10.80
-3.4%
$11.21
$3.89
$14.75
$252.40M1.16481,488 shs114,747 shs
Luminex Co. stock logo
LMNX
Luminex
$36.99
$36.90
$20.61
$41.69
$1.75B0.56873,093 shsN/A
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
+6.33%-0.99%-20.32%-33.17%-55.11%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
0.00%0.00%0.00%0.00%0.00%
Glaukos Co. stock logo
GKOS
Glaukos
+0.68%+2.39%+6.37%+11.85%+81.92%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
+1.64%-6.91%-3.87%+65.88%-90.41%
Luminex Co. stock logo
LMNX
Luminex
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AtriCure, Inc. stock logo
ATRC
AtriCure
3.6473 of 5 stars
4.54.00.00.01.92.50.6
Cantel Medical Corp. stock logo
CMD
Cantel Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Glaukos Co. stock logo
GKOS
Glaukos
3.5739 of 5 stars
2.41.00.04.43.72.50.6
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
3.8674 of 5 stars
3.33.00.04.62.60.00.6
Luminex Co. stock logo
LMNX
Luminex
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AtriCure, Inc. stock logo
ATRC
AtriCure
3.00
Buy$49.78126.37% Upside
Cantel Medical Corp. stock logo
CMD
Cantel Medical
N/AN/AN/AN/A
Glaukos Co. stock logo
GKOS
Glaukos
2.82
Moderate Buy$108.64-0.49% Downside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.67
Moderate Buy$96.00788.89% Upside
Luminex Co. stock logo
LMNX
Luminex
N/AN/AN/AN/A

Current Analyst Ratings

Latest CMD, GKOS, ATRC, INO, and LMNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2024
Glaukos Co. stock logo
GKOS
Glaukos
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$84.00 ➝ $125.00
5/2/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$57.00 ➝ $49.00
5/2/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.00
5/2/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$46.00 ➝ $40.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$107.00 ➝ $112.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$108.00 ➝ $110.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00 ➝ $125.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$103.00 ➝ $110.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$108.00 ➝ $113.00
4/23/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$32.00
4/11/2024
Glaukos Co. stock logo
GKOS
Glaukos
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$85.00 ➝ $100.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AtriCure, Inc. stock logo
ATRC
AtriCure
$414.60M2.52N/AN/A$9.84 per share2.23
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$1.02B3.52$3.38 per share23.78$17.31 per share4.64
Glaukos Co. stock logo
GKOS
Glaukos
$326.43M16.84N/AN/A$9.46 per share11.54
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$832.01K303.36N/AN/A$5.16 per share2.09
Luminex Co. stock logo
LMNX
Luminex
$417.40M4.19$1.12 per share32.98$11.13 per share3.32

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AtriCure, Inc. stock logo
ATRC
AtriCure
-$30.44M-$0.80N/AN/AN/A-8.98%-7.85%-6.05%7/23/2024 (Estimated)
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$13.71M$1.6569.2828.911.634.72%12.13%4.45%N/A
Glaukos Co. stock logo
GKOS
Glaukos
-$134.66M-$2.88N/AN/AN/A-43.15%-24.69%-12.27%8/7/2024 (Estimated)
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$135.12M-$7.56N/AN/AN/A-16,238.91%-79.86%-57.71%5/13/2024 (Confirmed)
Luminex Co. stock logo
LMNX
Luminex
$15.17M$0.3272.5330.83N/A5.39%4.66%2.91%N/A

Latest CMD, GKOS, ATRC, INO, and LMNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2024N/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$1.08N/A+$1.08N/AN/AN/A  
5/1/2024Q1 2024
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.23-$0.25-$0.02-$0.22$106.86 million$108.90 million      
5/1/2024Q1 2024
Glaukos Co. stock logo
GKOS
Glaukos
-$0.58-$0.70-$0.12-$0.58$79.60 million$85.60 million    
2/21/2024Q4 2023
Glaukos Co. stock logo
GKOS
Glaukos
-$0.56-$0.63-$0.07-$0.51$81.00 million$82.40 million    
2/15/2024Q4 2023
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.22-$0.21+$0.01-$0.21$103.68 million$106.50 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$0.210.26%N/A12.73%N/A
Glaukos Co. stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Luminex Co. stock logo
LMNX
Luminex
$0.401.08%N/A125.00%N/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AtriCure, Inc. stock logo
ATRC
AtriCure
0.16
4.00
2.83
Cantel Medical Corp. stock logo
CMD
Cantel Medical
1.16
2.72
2.00
Glaukos Co. stock logo
GKOS
Glaukos
0.78
5.38
4.68
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
3.60
3.60
Luminex Co. stock logo
LMNX
Luminex
0.52
8.37
6.08

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
84.13%
Glaukos Co. stock logo
GKOS
Glaukos
99.04%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Luminex Co. stock logo
LMNX
Luminex
87.76%

Insider Ownership

CompanyInsider Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
3.20%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
10.70%
Glaukos Co. stock logo
GKOS
Glaukos
6.40%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50%
Luminex Co. stock logo
LMNX
Luminex
6.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,20047.59 million46.07 millionOptionable
Cantel Medical Corp. stock logo
CMD
Cantel Medical
3,66944.51 millionN/AOptionable
Glaukos Co. stock logo
GKOS
Glaukos
90750.37 million46.98 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
12223.37 million22.79 millionOptionable
Luminex Co. stock logo
LMNX
Luminex
1,32547.31 millionN/AOptionable

CMD, GKOS, ATRC, INO, and LMNX Headlines

SourceHeadline
Flash News: OKX Wallet Web Extension Expands to Include Luminex AccessFlash News: OKX Wallet Web Extension Expands to Include Luminex Access
finance.yahoo.com - April 18 at 7:42 AM
Luminex-Puritas JV secures Mallavi Urban Water Supply Scheme contract in MullaitivuLuminex-Puritas JV secures Mallavi Urban Water Supply Scheme contract in Mullaitivu
ft.lk - March 24 at 4:40 PM
ERS electronic introduces the first semi-automatic machine of its Luminex product line featuring groundbreaking PhotoThermal debonding technologyERS electronic introduces the first semi-automatic machine of its Luminex product line featuring groundbreaking PhotoThermal debonding technology
finance.yahoo.com - March 13 at 8:18 AM
Adventus and Luminex Announce Merger to Create a Growth-Focused Copper-Gold Company in EcuadorAdventus and Luminex Announce Merger to Create a Growth-Focused Copper-Gold Company in Ecuador
finance.yahoo.com - November 21 at 6:05 PM
Luminex Resources Corp (LR)Luminex Resources Corp (LR)
investing.com - October 28 at 5:46 AM
Luminex Resources Announces Excellent Metallurgical Results at Cuyes WestLuminex Resources Announces Excellent Metallurgical Results at Cuyes West
juniorminingnetwork.com - September 27 at 10:41 AM
Luminex Announces Excellent Metallurgical Results at Cuyes WestLuminex Announces Excellent Metallurgical Results at Cuyes West
newswire.ca - September 27 at 10:41 AM
Streck Quality Controls for DiaSorins Luminex Sepsis Tests Receive FDA ClearanceStreck Quality Controls for DiaSorin's Luminex Sepsis Tests Receive FDA Clearance
360dx.com - September 25 at 3:28 PM
Luminex (LMNX) Receives FDA Approval for NxTAG RPPLuminex (LMNX) Receives FDA Approval for NxTAG RPP
finance.yahoo.com - September 24 at 1:13 AM
Luminex Has Entered into Discussions with Anglo American to Amend the Terms of the Pegasus Earn-InLuminex Has Entered into Discussions with Anglo American to Amend the Terms of the Pegasus Earn-In
prnewswire.com - September 20 at 7:04 AM
Luminex Reaches Agreement with a Second Association of Artisanal Miners Around Condor NorthLuminex Reaches Agreement with a Second Association of Artisanal Miners Around Condor North
finance.yahoo.com - September 8 at 8:55 AM
Stenograph Announces the Release of the Bordeaux Luminex IIStenograph Announces the Release of the Bordeaux Luminex II
marketscale.com - September 6 at 5:54 PM
Luminex moots JV with PuritasLuminex moots JV with Puritas
ft.lk - September 5 at 8:57 PM
Luminex Announces an Update on the Pegasus Earn-inLuminex Announces an Update on the Pegasus Earn-in
finance.yahoo.com - August 23 at 6:19 PM
Luminex reaches ‘historic’ agreement with informal miners around Ecuador gold projectLuminex reaches ‘historic’ agreement with informal miners around Ecuador gold project
mining.com - August 22 at 9:51 PM
Luminex Reaches Historic Agreement with Informal Miners Around Condor NorthLuminex Reaches Historic Agreement with Informal Miners Around Condor North
finance.yahoo.com - August 21 at 7:42 AM
New BRC69 Token Standard Promises 90% Savings for Bitcoin’s Ordinal InscriptionsNew BRC69 Token Standard Promises 90% Savings for Bitcoin’s Ordinal Inscriptions
news.bitcoin.com - July 5 at 2:07 AM
Bitcoin Ordinals Launchpad Luminex Announces BRC-69 Standard to Simplify Recursive InscriptionsBitcoin Ordinals Launchpad Luminex Announces BRC-69 Standard to Simplify Recursive Inscriptions
coinspeaker.com - July 4 at 9:02 AM
Stenograph Announces the Release of the Graphite Luminex IIStenograph Announces the Release of the Graphite Luminex II
marketscale.com - June 21 at 11:38 PM
Luminex Resources drill results reveal high-grade intercept in New Breccia Pipe at Cuyes WestLuminex Resources drill results reveal high-grade intercept in New Breccia Pipe at Cuyes West
finance.yahoo.com - May 30 at 3:02 PM
Luminex Resources drill results showing high-grade intercept in New Breccia Pipe at Cuyes WestLuminex Resources drill results showing high-grade intercept in New Breccia Pipe at Cuyes West
proactiveinvestors.com - May 29 at 2:56 PM
Global Chemiluminescence Immunoassay (Clia) Analyzers Market ... - Digital JournalGlobal Chemiluminescence Immunoassay (Clia) Analyzers Market ... - Digital Journal
news.google.com - May 14 at 10:05 AM
Molecular Biology Analyzers Market: Size & Trends Shows a Rapid ... - Cottonwood Holladay JournalMolecular Biology Analyzers Market: Size & Trends Shows a Rapid ... - Cottonwood Holladay Journal
news.google.com - May 13 at 1:37 AM
Flow Cytometer System Market Size, Development Data, Growth ... - StreetBuzzFlow Cytometer System Market Size, Development Data, Growth ... - StreetBuzz
news.google.com - May 13 at 1:37 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AtriCure logo

AtriCure

NASDAQ:ATRC
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Cantel Medical logo

Cantel Medical

NYSE:CMD
Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Life Sciences segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratories, food and beverage, and commercial industrial customers, as well as microbiological testing services. The company's Dental segment offers hand and powered dental instruments, instrument reprocessing and sterility assurance products, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under various third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.
Glaukos logo

Glaukos

NYSE:GKOS
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Inovio Pharmaceuticals logo

Inovio Pharmaceuticals

NASDAQ:INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Luminex logo

Luminex

NASDAQ:LMNX
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.